Oncad for DynaCAD is an FDA-cleared, fully automated morphological system for the detection and analysis by a radiologist of suspicious breast lesions. It uses a patented mathematical algorithm to analyze the entire breast and draw a physician’s attention to abnormal morphology during a contrast-enhanced breast MRI. This approach also delineates the extent of the disease by measuring margin sharpness to determine the degree of lesion vascularization. The suspicious lesions are marked with a color overlay, light pink for moderate suspicion and dark pink for highly suspicious lesions.

For more information: www.invivocorp.com


Additional Content

News | Radiology Imaging

Nov. 2, 2026 — Neurophet and RapidAI have partnered to integrate Neurophet’s advanced neurodegenerative brain imaging ...

Time November 04, 2026
arrow
News | Women's Health

Oct. 29, 2026 — Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive ...

Time October 30, 2026
arrow
News | Radiology Imaging

Oct. 19, 2026 — Paradromics Inc. has announced a collaboration with Siemens Healthineers to develop an advanced ...

Time October 26, 2026
arrow
News | Lung Imaging

Oct. 20, 2026 — Optellum has announced that its Virtual Nodule Clinic (VNC) with Lung Cancer Prediction (LCP) AI is ...

Time October 21, 2026
arrow
News | FDA

Oct.7, 2026 – MRI2CT Inc. has received FDA 510(k) clearance for NextMR, its AI powered imaging platform, for generating ...

Time October 07, 2026
arrow
Subscribe Now